Fulltext

Clinical Assessment of Potential Drug Interactions of Faldaprevir, a Hepatitis C Virus Protease Inhibitor, With Darunavir/Ritonavir, Efavirenz, and Tenofovir

Sabo, John P. ; Kort, Jens ; Ballow, Charles ; Haschke, Manuel ; Battegay, Manuel ; Fuhr, Rainard ; Girlich, Birgit ; Schobelock, Michael ; Feifel, Ulrich ; Lang, Benjamin ; Li, Yongmei ; Elgadi, Mabrouk

In: Clinical Infectious Diseases, 2014, vol. 59, no. 10, p. 1420-1428

Add to personal list
    Title
    • Clinical Assessment of Potential Drug Interactions of Faldaprevir, a Hepatitis C Virus Protease Inhibitor, With Darunavir/Ritonavir, Efavirenz, and Tenofovir
    Author
    • Sabo, John P.. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut
    • Kort, Jens. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut
    • Ballow, Charles. Buffalo Clinical Research Center, New York
    • Haschke, Manuel. University Hospital Basel, Switzerland
    • Battegay, Manuel. University Hospital Basel, Switzerland
    • Fuhr, Rainard. PAREXEL International GmbH, Berlin, Germany
    • Girlich, Birgit. Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland
    • Schobelock, Michael. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut
    • Feifel, Ulrich. Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim
    • Lang, Benjamin. Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    • Li, Yongmei. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut
    • Elgadi, Mabrouk. Boehringer Ingelheim Ltd, Burlington, Ontario, Canada
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Clinical Infectious Diseases, 2014, vol. 59, no. 10, p. 1420-1428. Oxford University Press
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:303062
    Summary
    Faldaprevir is a potent hepatitis C virus NS3/4A protease inhibitor. The findings from 3 phase 1 studies reported here suggest that faldaprevir can be safely coadministered with commonly used antiretrovirals